Practice changing cervical cancer clinical trials.

• Cemiplimab treatment is efficacious in patients with recurrent or metastatic cervical cancer (cvx ca). • Pembrolizumab with chemotherapy is active and FDA approved in first line treatment of recurrent/metastatic PDL-1 + cvx ca. • Tisotumab Vedotin (TV) received FDA accelerated approval for treatment of recurrent/metastatic cvx ca after chemotherapy. • Transformative advances in cvx ca result from collaborations with GOG-P, ENGOT, other global partners and industry sponsors. • Sequencing includes:1) pembrolizumab with first line chemotherapy 2) TV in second line or pembrolizumab if checkpoint naïve. [ABSTRACT FROM AUTHOR]